{"transactions":[{"id":719171,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":33216,"kind":"person","name":"CLAUSEN PETER","position":1,"cik":"0001605411","reported_name":"CLAUSEN PETER","relationship":{"officer":true,"officer_title":"CSO/COO"}}],"security":"Option to purchase common stock","published_at":"2026-07-03T01:31:19.000Z","date":"2026-06-29","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One third of the options are exercisable as of June 30, 2027 and the balance vest quarterly over the subsequent two years."}],"balance_after":65000,"derivative":{"exercise_price":1.01,"expiration_date":"2036-06-29","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001437749-26-022670","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774926022670/rdgdoc.xml","form_type":"4"}},{"id":1076656,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":33216,"kind":"person","name":"CLAUSEN PETER","position":1,"cik":"0001605411","reported_name":"CLAUSEN PETER","relationship":{"officer":true,"officer_title":"CSO/COO"}}],"security":"Option to purchase common stock","published_at":"2025-08-04T13:06:50.000Z","date":"2018-08-09","kind":"exercise","planned":false,"acquired":false,"shares":183853,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.4,"exercise_date":"2018-08-09","expiration_date":"2025-08-08","underlying":"Common Stock","underlying_shares":183853},"source":{"system":"sec-edgar","filing":"0001437749-25-024493","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774925024493/rdgdoc.xml","form_type":"4"}},{"id":1076655,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":33216,"kind":"person","name":"CLAUSEN PETER","position":1,"cik":"0001605411","reported_name":"CLAUSEN PETER","relationship":{"officer":true,"officer_title":"CSO/COO"}}],"security":"Common Stock","published_at":"2025-08-04T13:06:50.000Z","date":"2025-07-31","kind":"exercise","planned":false,"acquired":true,"shares":183853,"price":0.4,"value":73541.2,"ownership":{"direct":true},"balance_after":770054,"source":{"system":"sec-edgar","filing":"0001437749-25-024493","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774925024493/rdgdoc.xml","form_type":"4"}},{"id":1507611,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":33216,"kind":"person","name":"CLAUSEN PETER","position":1,"cik":"0001605411","reported_name":"CLAUSEN PETER","relationship":{"officer":true,"officer_title":"CSO/COO"}}],"security":"Common Stock","published_at":"2024-05-21T19:13:21.000Z","date":"2024-05-20","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0.75,"value":11250.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction approved by Board of Directors of Issuer and Non-Employee Directors"}],"balance_after":586201,"source":{"system":"sec-edgar","filing":"0001437749-24-017814","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774924017814/rdgdoc.xml","form_type":"4"}},{"id":1703668,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":33216,"kind":"person","name":"CLAUSEN PETER","position":1,"cik":"0001605411","reported_name":"CLAUSEN PETER","relationship":{"officer":true,"officer_title":"CSO/COO"}}],"security":"Common Stock","published_at":"2023-12-20T19:04:23.000Z","date":"2023-12-19","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0.5,"value":10000.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction approved by Board of Directors of Issuer and Non-Employee Directors"}],"balance_after":571201,"source":{"system":"sec-edgar","filing":"0001437749-23-034982","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774923034982/rdgdoc.xml","form_type":"4"}},{"id":1816937,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":33216,"kind":"person","name":"CLAUSEN PETER","position":1,"cik":"0001605411","reported_name":"CLAUSEN PETER","relationship":{"officer":true,"officer_title":"CSO/COO"}}],"security":"Common Stock","published_at":"2023-08-03T20:18:21.000Z","date":"2023-08-01","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":2,"value":50000.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction approved by Board of Directors of Issuer and Non-Employee Directors"}],"balance_after":551201,"source":{"system":"sec-edgar","filing":"0001437749-23-021950","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774923021950/rdgdoc.xml","form_type":"4"}},{"id":2231816,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":33216,"kind":"person","name":"CLAUSEN PETER","position":1,"cik":"0001605411","reported_name":"CLAUSEN PETER","relationship":{"officer":true,"officer_title":"CSO/COO"}}],"security":"Option to Purchase Common Stock","published_at":"2022-06-15T22:18:32.000Z","date":"2022-06-06","kind":"grant","acquired":true,"shares":275000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The grant of these options was approved by the issuer's Board of Directors on March 4, 2022, subject to stockholder approval of an amendment to increase the number of shares available for issuance under the issuer's 2016 Omnibus Incentive Compensation Plan pursuant to which the options were granted.  Stockholder approval was obtained by means of a written consent and the issuer filed a related Information Statement on Schedule 14C with the SEC on April 27, 2022.  The stockholder approval became effective on June 6, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-third exercisable immediately on 03/04/2022 and the remainder exercisable quarterly over three years."}],"balance_after":275000,"derivative":{"exercise_price":0.75,"exercise_date":"2022-03-04","expiration_date":"2032-03-04","underlying":"Common Stock","underlying_shares":275000},"source":{"system":"sec-edgar","filing":"0001437749-22-015095","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922015095/rdgdoc.xml","form_type":"4"}},{"id":2286887,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":33216,"kind":"person","name":"CLAUSEN PETER","position":1,"cik":"0001605411","reported_name":"CLAUSEN PETER","relationship":{"officer":true,"officer_title":"CSO/COO"}}],"security":"Common Stock","published_at":"2022-05-02T16:23:08.000Z","date":"2022-04-29","kind":"grant","acquired":true,"shares":25000,"price":1,"value":25000.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction approved by Board of Directors of Issuer and Non-Employee Directors"}],"balance_after":526201,"source":{"system":"sec-edgar","filing":"0001437749-22-010381","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922010381/rdgdoc.xml","form_type":"4"}},{"id":2290520,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":33216,"kind":"person","name":"CLAUSEN PETER","position":1,"cik":"0001605411","reported_name":"CLAUSEN PETER","relationship":{"officer":true,"officer_title":"CSO/COO"}}],"security":"Option to Purchase Common Stock","published_at":"2022-04-27T01:32:04.000Z","date":"2022-03-04","kind":"grant","acquired":true,"shares":43328,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Granted in settlement of compensation liability for period January 1, 2019 through April 30, 2019"}],"balance_after":43328,"derivative":{"exercise_price":0.5,"exercise_date":"2022-03-04","expiration_date":"2032-03-04","underlying":"Common Stock","underlying_shares":43328},"source":{"system":"sec-edgar","filing":"0001437749-22-009788","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922009788/rdgdoc.xml","form_type":"4"}},{"id":3710137,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":33216,"kind":"person","name":"CLAUSEN PETER","position":1,"cik":"0001605411","reported_name":"CLAUSEN PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Option to Purchase Common Stock","published_at":"2019-01-03T16:45:26.000Z","date":"2018-12-31","kind":"grant","acquired":true,"shares":81250,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":81250,"derivative":{"exercise_price":0.4,"exercise_date":"2018-12-31","expiration_date":"2025-12-31","underlying":"COMMON STOCK","underlying_shares":81250},"source":{"system":"sec-edgar","filing":"0001091596-19-000002","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000109159619000002/primary_doc.xml","form_type":"4"}},{"id":3846475,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":33216,"kind":"person","name":"CLAUSEN PETER","position":1,"cik":"0001605411","reported_name":"CLAUSEN PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Option to Purchase Common Stock","published_at":"2018-08-13T19:44:35.000Z","date":"2018-08-09","kind":"grant","acquired":true,"shares":183853,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":183853,"derivative":{"exercise_price":0.4,"exercise_date":"2018-08-09","expiration_date":"2025-08-09","underlying":"COMMON STOCK","underlying_shares":183853},"source":{"system":"sec-edgar","filing":"0001605411-18-000001","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000160541118000001/primary_doc.xml","form_type":"4"}},{"id":4493256,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":33216,"kind":"person","name":"CLAUSEN PETER","position":1,"cik":"0001605411","reported_name":"CLAUSEN PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Option to purchase Common Stock","published_at":"2017-01-12T01:19:52.000Z","date":"2017-01-09","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The grant of these options was approved by the issuer's board of directors on July 1, 2016, subject to stockholder approval of the 2016 Omnibus Incentive Compensation Plan under which the options were granted. Stockholder approval was obtained by means of a written consent and the issuer filed a related Information Statement on Schedule 14C with the SEC on November 25, 2016. The stockholder approval became effective on January 9, 2017. The option grant disclosed herein does not include options to purchase 95,000 shares subject to performance conditions, which have not yet vested and are therefore not yet reportable on Form 4."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Of these options, 40,000 vested on 9/29/16 and 40,000 will vest on 12/31/17."}],"balance_after":80000,"derivative":{"exercise_price":1,"expiration_date":"2026-07-01","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001144204-17-001883","document":"v456666_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000114420417001883/v456666_4.xml","form_type":"4"}}]}